title: The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.
abstract: OBJECTIVE
  Diabetes mellitus is an exploding epidemic costing billions of dollars yearly. Type 2 diabetes mellitus is characterized by insulin resistance and is closely associated with arterial hypertension. Emerging literature has demonstrated that modulation of the renin-angiotensin-aldosterone system by use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers leads to improved insulin sensitivity, glycemic control and possibly prevention of type 2 diabetes mellitus.
  
  
  RESULTS
  Several major studies investigating angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use in either hypertensive or heart failure patients have found lower incidence of type 2 diabetes mellitus when compared with placebo, beta-blocker, calcium-channel blocker or diuretic. None of these trials, however, studied prevention of diabetes as a primary endpoint. The Dream Trial and upcoming NAVIGATOR, ONTARGET/TRANSCEND trials specifically look at the prevention of diabetes as a primary endpoint. Several studies have evaluated possible mechanisms of how the renin-angiotensin-aldosterone system can alter insulin sensitivity and glycemic control.
  
  
  CONCLUSIONS
  This review will focus on the recent literature that demonstrates renin-angiotensin-aldosterone system modulation and its effects on diabetes prevention, glycemic control and insulin sensitivity, as well as possible mechanisms for achieving this goal.
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University, Nashville, Tennesse 37232-0475, USA.
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Perkins
authors.forename: Stephen N
authors.initials: SN
authors.lastname: Davis
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000503:physiopathology* / Q000517:prevention & control; D006706:Homeostasis; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D007328:Insulin / Q000502:physiology*; D007333:Insulin Resistance / Q000502:physiology*; D044140:Receptor, Angiotensin, Type 1; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose; D007328:Insulin; D044140:Receptor, Angiotensin, Type 1; D000804:Angiotensin II